- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Adriaan Voors on Possible Unexplained Benefits of SGLT2 Inhibitors
Adriaan Voors, MD, University Medical Center Groningen, the Netherlands, discusses how and why sodium-glucose co-transporter 2 (SGLT2) inhibitors act so quickly for patients with heart failure.
Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, discusses how and why sodium-glucose co-transporter 2 (SGLT2) inhibitors act so quickly for patients with heart failure.
Transcript
Can you explain why SGLT2 inhibitors work so quickly?
On the one hand, yes, they work quickly. As you can see in the chronic trials, the survival curves separate really from early on. If I’m honest, with the survival curves that we’ve seen with traditional end points, the time to death and heart failure event, which were nonprespecified end points, were significantly reduced. If you look at the Kaplan Meier curves, they separate only after 15 days, and if it were only the diuretic effects, I would have expected it to be more prevalent already in hospital to get a more early separation of the curves.
Now, we haven’t looked at the quality of life over time. We will have secondary manuscripts; that’s one of the very important ones we will be currently looking at. So it might be that improvement in the symptoms might be early on, but in the heart clinical endpoints like death or hospital readmission, the curves separate only after 15 days—so that may be indicating something else is going on with these drugs as well, besides decongestant and diuresis.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
